<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Nguyen-Vu T</submitter><funding>NCI NIH HHS</funding><pagination>42159-42171</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC5173124</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>7(27)</volume><pubmed_abstract>Colon cancer is a common cause of cancer death in the Western world. Accumulating evidence supports a protective role of estrogen via estrogen receptor beta (ER?) but the mechanism of action is not known. Here, we elucidate a molecular mechanism whereby ER? represses the oncogenic prospero homebox 1 (PROX1) through the upregulation of miR-205. We show that PROX1 is a potential target of miR-205 and that in clinical specimens from The Cancer Genome Atlas data, ER? and miR-205 are decreased in colorectal cancer tissue compared to non-tumorous colon, while PROX1 levels are increased. Through mechanistic studies in multiple colorectal cancer cell lines, we show that ER? upregulates miR-205, and that miR-205 targets and represses PROX1 through direct interaction with its 3'UTR. Through the generation of intestine-specific ER? knockout mice, we establish that this pathway is correspondingly regulated in normal intestinal epithelial cells in vivo. Functionally, we demonstrate that miR-205 decreases cell proliferation and decreases migratory and invasive potential of colon cancer cells, leading to a reduction of micrometastasis in vivo. In conclusion, ER? in both normal and cancerous colon epithelial cells upregulates miRNA-205, which subsequently reduces PROX1 through direct interaction with its 3'UTR. This results in reduced proliferative and metastatic potential of the cells. Our study proposes a novel pathway that may be exploited using ER?-selective agonists and/or miR-205-replacement therapy in order to improve preventive and therapeutic approaches against colon cancer.</pubmed_abstract><journal>Oncotarget</journal><pubmed_title>Estrogen receptor beta reduces colon cancer metastasis through a novel miR-205 - PROX1 mechanism.</pubmed_title><pmcid>PMC5173124</pmcid><funding_grant_id>R01 CA172437</funding_grant_id><pubmed_authors>McCollum CW</pubmed_authors><pubmed_authors>Mesmar F</pubmed_authors><pubmed_authors>Nguyen-Vu T</pubmed_authors><pubmed_authors>Bondesson M</pubmed_authors><pubmed_authors>Saxena A</pubmed_authors><pubmed_authors>Mukhopadhyay S</pubmed_authors><pubmed_authors>Wang J</pubmed_authors><pubmed_authors>Gustafsson JA</pubmed_authors><pubmed_authors>Williams C</pubmed_authors></additional><is_claimable>false</is_claimable><name>Estrogen receptor beta reduces colon cancer metastasis through a novel miR-205 - PROX1 mechanism.</name><description>Colon cancer is a common cause of cancer death in the Western world. Accumulating evidence supports a protective role of estrogen via estrogen receptor beta (ER?) but the mechanism of action is not known. Here, we elucidate a molecular mechanism whereby ER? represses the oncogenic prospero homebox 1 (PROX1) through the upregulation of miR-205. We show that PROX1 is a potential target of miR-205 and that in clinical specimens from The Cancer Genome Atlas data, ER? and miR-205 are decreased in colorectal cancer tissue compared to non-tumorous colon, while PROX1 levels are increased. Through mechanistic studies in multiple colorectal cancer cell lines, we show that ER? upregulates miR-205, and that miR-205 targets and represses PROX1 through direct interaction with its 3'UTR. Through the generation of intestine-specific ER? knockout mice, we establish that this pathway is correspondingly regulated in normal intestinal epithelial cells in vivo. Functionally, we demonstrate that miR-205 decreases cell proliferation and decreases migratory and invasive potential of colon cancer cells, leading to a reduction of micrometastasis in vivo. In conclusion, ER? in both normal and cancerous colon epithelial cells upregulates miRNA-205, which subsequently reduces PROX1 through direct interaction with its 3'UTR. This results in reduced proliferative and metastatic potential of the cells. Our study proposes a novel pathway that may be exploited using ER?-selective agonists and/or miR-205-replacement therapy in order to improve preventive and therapeutic approaches against colon cancer.</description><dates><release>2016-01-01T00:00:00Z</release><publication>2016 Jul</publication><modification>2021-02-20T06:33:39Z</modification><creation>2019-03-27T02:32:06Z</creation></dates><accession>S-EPMC5173124</accession><cross_references><pubmed>27283988</pubmed><doi>10.18632/oncotarget.9895</doi></cross_references></HashMap>